Equity Opportunities 17, Ll... Net Worth

The estimated Net Worth of Equity Opportunities 17, Ll... is at least $106 Million dollars as of 17 July 2023. Equity Ll owns over 333,333 units of Savara Inc stock worth over $105,715,860 and over the last few years Equity sold SVRA stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Equity Ll SVRA stock SEC Form 4 insiders trading

Equity has made over 1 trades of the Savara Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Equity bought 333,333 units of SVRA stock worth $999,999 on 17 July 2023.

The largest trade Equity's ever made was buying 333,333 units of Savara Inc stock on 17 July 2023 worth over $999,999. On average, Equity trades about 333,333 units every 0 days since 2023. As of 17 July 2023 Equity still owns at least 24,471,264 units of Savara Inc stock.

You can see the complete history of Equity Ll stock trades at the bottom of the page.

Insiders trading at Savara Inc

Over the last 7 years, insiders at Savara Inc have traded over $2,203,958 worth of Savara Inc stock and bought 6,103,761 units worth $15,290,245 . The most active insiders traders include Forest Baskett, Scott D Sandell, and Anthony A. Jr. Florence. On average, Savara Inc executives and independent directors trade stock every 29 days with the average trade being worth of $348,922. The most recent stock trade was executed by Matthew Pauls on 28 December 2023, trading 84,000 units of SVRA stock currently worth $395,640.

What does Savara Inc do?

savara pharmaceuticals is an emerging specialty pharmaceutical company developing innovative pulmonary drugs for the treatment of serious and life-threatening conditions. the company’s lead product, aerovanc is the first dry powder inhaled antibiotic for the treatment of methicillin-resistant staphylococcus aureus (mrsa) infection in patients with cystic fibrosis (cf). for more information, please see savara’s website at www.savarapharma.com or www.aerovanc.com

Complete history of Equity Ll stock trades at Savara Inc

Savara Inc executives and stock owners

Savara Inc executives and other stock owners filed with the SEC include:

• Dr. Badrul A. Chowdhury M.D., Ph.D.,
  Chief Medical Officer
• David Lowrance,
  Chief Financial Officer, Secretary
• David L. Lowrance,
  CFO & Sec.
• Ricky Sun,
  Independent Director
• Annigje van Es-Johansson,
  Independent Director
• Badrul Chowdhury,
  Chief Medical Officer
• Anne Erickson,
  IR Contact Officer
• David Ramsay,
  Independent Director
• Matthew Pauls,
  Chairman of the Board, Interim Chief Executive Officer
• Joseph McCracken,
  Independent Director
• Richard Hawkins,
  Independent Director
• Nevan Elam,
  Independent Director
• Dr. Peter Clarke Ph.D.,
  Exec. VP of Global Technical Operations
• Charles LaPree,
  Sr. VP of Global Regulatory Affairs & Quality Assurance
• Brian Maurer,
  Head of Clinical Operations
• Dr. Dhaval Desai M.D.,
  Head of Clinical Devel.
• Kate McCabe,
  Sr. VP of Legal Affairs
• Robert N Neville,
  Chief Executive Officer
• Yuri Pikover,
  Director
• Jaakko Taneli Jouhikainen,
  See Remarks
• Es Johansson An Van,
  Director
• Forest Baskett,
  10% owner
• Equity Opportunities 17, Ll...,
  
• Rick Yang,
  10% owner
• Paul Edward Walker,
  10% owner
• Scott D Sandell,
  10% owner
• Edward T Mathers,
  10% owner
• Mohamad Makhzoumi,
  10% owner
• Carmen Chang,
  10% owner
• Anthony A. Jr. Florence,
  10% owner
• Ali Behbahani,
  10% owner
• Raymond Dennis Pratt,
  Chief Medical Officer
• Robert Matthew Lutz,
  Chief Operating Officer